$7900 | Single User
$20500 | Global License
$25800 | Site License

Renal Cell Carcinoma: KOL Insight
[Published by FirstWord Pharma]

Published by FirstWord Pharma: 01 Feb 2015 | 191 | In Stock
Related Topics: Cancer , Novartis , Pfizer , Renal Cell Carcinoma , Roche



Will new checkpoint inhibitors revive immunotherapy in RCC?

Renal Cell Carcinoma: KOL Insight offers opinions of 12 leading US and European KOLs that present business-critical insights for branded pharma and the drug discovery community. Gain insights on what leading clinicians think about current treatment options, new therapies, the critical role of clinical research and the factors that influence oncologists’ prescribing decisions.

With the expected approval and launch of PD-1 inhibitors such BMS’ Opdivo (nivolumab) the options for first- and second-line treatment of RCC are expected to widen over time and impact currently available therapies. While initially these new products will be launched as monotherapies for second-line treatment there is wide anticipation that, in combination, they will ultimately take a commanding role in first-line treatment.

This report gives insights into when and why clinicians will use these new therapies and how it influences their prescribing decisions. In addition, readers will gain insights on which product combinations are most favoured and why, which products are most likely to be affected as the new treatment paradigm takes shape and the strategic lessons for drug discovery and development companies.

Therapy Trends reports deliver critical and unbiased intelligence derived from in-depth interviews with the world’s foremost thought leaders on the current and future treatment landscapes in major disease areas. Research is focused on the major battlegrounds for market share and answers critical business questions about potential product positioning and competitiveness. Through continuous monitoring and frequent re-engagement with stakeholders, the FirstWord Therapy Trends analyst team delivers quarterly updates with each report ensuring insights remain current and relevant.

Puchase Reasons

Top Takeaways

  • Formulate effective strategies for clinician communication by understanding KOL concerns

  • Find key areas for strategic and tactical action by understanding the important factors affecting the RCC sector

  • Design clinical trials which are more likely to lead to strong product positioning (e.g. more effective comparator, population and endpoint selection)

  • Identify companies/products that are likely to move down the treatment pathway as new therapies gain market share

  • Make more informed decisions about which R&D programmes warrant investment or discontinuation

  • Position your early stage research and licencing plans to exploit future competitor weaknesses

  • Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes (CheckMate-025, METEOR, IMPRINT, ADAPT, SWITCH-II, CROSS-J-RCC, FLIPPER, ASSURE, S-TRAC, PROTECT, and ATLAS)

  • Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions

  • Evaluate the changing competitive landscape and identify solutions that aid KOLs in their practice

  • Review next generation development approaches and identify opportunity areas

  • Gain Answers to Key Questions

  • What clinical advantages do KOLs see in GSK’s VEGF TKI Votrient (pazobanib) over Pfizer’s Sutent (sunitinib) and how might this play out?

  • What head-to-head clinical trials would help KOLs when making second line treatment decisions?

  • What are the future prospects for mTOR inhibitors such as Novartis’Afinitor (everolimus) and why might KOL’s prefer Pfizer’s Inlyta and the VEGF TKI options?

  • What cost/benefit consideration should BMS consider for Opdivo in Europe?

  • How might the availability of checkpoint inhibitors give a boost to Roche’s Avastin (bevacizumab)?

  • What is the potential of Argos’ AGS-003 and Inmatics’ renal cancer vaccine IMA901 – is their window of opportunity gone?

  • How might the future treatment landscape and late-stage hopefuls influence drug development companies when making their portfolio decisions?

  • Key Opinion Leaders

    North America

  • Michael B. Atkins, MD - Georgetown University School of Medicine, Washington, DC

  • Robert Figlin, MD, FACP Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai, CA

  • James J. Hsieh, MD, PhD, Memorial Sloan Kettering Cancer Center, NY

  • Robert J. Motzer, MD, Memorial Sloan Kettering Cancer Center, NY Brian Rini, MD, Case Western Reserve University,OH

  • Europe

  • Bernard Escudier, MD Institut Gustave Roussy, France Emilio Esteban Hospital Universitario Central de Asturias, Oviedo, Spain

  • Camillo Porta, MD, University of Pavia, Italy Prof

  • Thomas Powles, MBBS, MRCP, MD Barts Cancer Institute, UK

  • Cora Sternberg, MD Institut Gustave Roussy, France

  • 2 anonymous German KOLs

  • Report Features

  • Insightful drug and development analysis with “real world” opinions of leading US and European KOLs not available elsewhere

  • Detailed and candid views on the future positioning and competitiveness of current and late-stage targeted and immune therapies

  • Essential insights which answer critical business questions in the RCC market for industry marketers, drug discovery/developer companies, clinical researchers and business planners

  • A comprehensive horizon scan for both branded and drug development companies

  • Update Bulletins Offer Ongoing Benefitss

    The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord’s guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.

    Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

  • Your Therapy Trends Report purchase entitles you to receive three Update Bulletins, which are published approximately every three months for 12 months following the report's publication date, February 2015.

  • You will receive a copy of each Update Bulletin once available, which are issued each quarter after the publication date
  • Table of Contents
    for Renal Cell Carcinoma: KOL Insight [Published by FirstWord Pharma]

    • 1.Executive Summary

      2.Research Objectives

      3.Research Focus

      4.Current treatment landscape




      5.2.1.Proleukin (aldesleukin; Prometheus Laboratories/Novartis)

      5.2.2.Interferon alpha (various brands)

      5.3.VEGF antibody

      5.3.1.Avastin (bevacizumab; Roche/Genentech)

      5.4.VEGF TKIs

      5.4.1.Nexavar (sorafenib; Bayer/Amgen)

      5.4.2.Sutent (sunitinib; Pfizer)

      5.4.3.Votrient (pazopanib; GlaxoSmithKline)

      5.4.4.Inlyta (axitinib; Pfizer)

      6.mTOR inhibitors

      6.1.Torisel (temsirolimus; Pfizer)

      6.2.Afinitor (everolimus; Novartis)



      7.2.Opdivo (nivolumab; Bristol-Myers Squibb)

      7.3.Cometriq (cabozantinib; Exelixis)

      7.4.Trebananib (AMG386; Amgen)

      7.5.IMA901 (renal cancer vaccine; immatics Biotechnologies GmbH)

      7.6.AGS-003 (Autologous Dendritic Cell Immunotherapy; Argos Therapeutics)

      8.Future treatment landscape



      10.1.North American KOLs

      10.2.European KOLs

    Additional Details


    FirstWord Pharma

    Publisher Information


    191 |

    Report Format


    FirstWord Pharma Reports

    Related Reports

    TitleDate PublishedPrice fromMore Details
    Global Renal Failure Partnering 2010 to 2016
    The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
    01 Oct 2016 by Current Partnering USD $1,495 More Info
    U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    SummaryU.S. Renal Care Inc. (U.S. Renal Care) is a healthcare service provider that offers in-center...
    10 May 2016 by Global Data USD $250 More Info
    Market Access Impact: Renal Cell Carcinoma (US)
    IntroductionMarket barriers boost net share for 6 major RCC treatments in US. Is your brand one of t...
    01 May 2016 by FirstWord Pharma USD $4,995 More Info
    Market Access Impact: Renal Cell Carcinoma (EU5)
    IntroductionMarket barriers cause net share loss for 5 major RCC treatments in Europe. Is your brand...
    01 May 2016 by FirstWord Pharma USD $4,995 More Info
    Medical Affairs Reputations: Renal Cell Carcinoma (US)
    IntroductionOpdivo’s medical affairs team working overtime to engage oncologists. Is it paying off?O...
    01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
    Medical Affairs Reputations: Renal Cell Carcinoma (EU5)
    Introduction4 medical affairs teams working hard to engage oncologists. Which one gets top marks? Eu...
    01 Apr 2016 by FirstWord Pharma USD $5,995 More Info
    U.S. Renal Care Inc. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
    SummaryU.S. Renal Care, Inc. (U.S. Renal Care) is a healthcare service provider that offers in-cente...
    17 Mar 2016 by Global Data USD $250 More Info
    NPS+ Renal Cell Carcinoma (US)
    IntroductionTwo brands lead the RCC treatment market. How does your brand stack up?US oncologists ma...
    01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
    NPS+ Renal Cell Carcinoma (EU5)
    IntroductionCompare 8 major RCC brands. Learn which one scores 6 times higher than any other?FirstVi...
    01 Feb 2016 by FirstWord Pharma USD $2,495 More Info
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015
    Chronic Kidney Disease (Chronic Renal Failure) Global Clinical Trials Review, H2, 2015SummaryGlobalD...
    30 Oct 2015 by Global Data USD $2,500 More Info

    This report is published by FirstWord Pharma

    Download Free Report Summary PDF

    Renal Cell Carcinoma: KOL Insight [Published by FirstWord Pharma] | Download PDF Summary

    Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

    Ordering Information

    Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

    Accepted Card Types


    Buy now using our secure payment system.

    We Stock...

    • 360i Research
    • 99Strategy
    • Allied Market Research
    • Asia Market Information & Development Co.
    • Azoth Analytics
    • BioInformant
    • Black Swan Analysis
    • Canadean
    • CBR Pharma Insights
    • CRI
    • Current Analysis
    • Current Partnering
    • Daedal Research
    • Data bridge
    • Delve Insight
    • DPI Research
    • FirstWord Pharma
    • Future Market Insights
    • GBI Research
    • Global Data
    • Global Markets Direct
    • Global Research and Data Services GRDS
    • GMR Data
    • HeyReport
    • HongChun
    • HTStec
    • ICD Research
    • iGATE Research
    • IMARC
    • Industry ARC
    • Inkwood Research
    • IQ4I
    • Jain PharmaBiotech
    • Kelly Scientific
    • La Merie
    • Lifescience Intellipedia
    • LP Information
    • Market Data Forecast
    • Market Research Future
    • Marketline
    • MarketsandMarkets
    • McDerson
    • MedMarket Diligence
    • Meticulous Research
    • MicroMarketMonitor
    • MIReports
    • Mordor Intelligence LLC
    • MP Advisors
    • Occams Business Research
    • Prof Research
    • Progressive Markets
    • ProGrow Pharma Partners
    • Renub
    • Research Impact
    • RNCOS
    • Rockville Research
    • S&P Consulting
    • StratisticsMRC
    • The Business Research Company
    • Triton Market Research
    • Venture Planning Group (VPG)